Project cooperationUpdated on 1 September 2025
Precision oncology for advanced targeted therapies
About
We seek collaborators on lung, breast, or colorectal cancer projects, and aim to expand our technology to all types of advanced targeted therapies, including small-molecule drugs and immunotherapies. With expertise in tyrosine kinase inhibitors for EGFR-, BRAF-, and ALK-driven NSCLC, our software assesses mutation effects. Our technology is clinically validated and helps de-risk pipelines, assess novel mutations, and optimize cohort selection, improving drug development and patient outcomes.
Stage
- Early
Type
- Research
- Financing
Organisation
Similar opportunities
Partnership
Partnership opportunities in advanced targeted therapies for cancer
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Service
In Silico Solutions to De-risk Drug Development and Empower Precision Medicine
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative human-based test models - In silico human models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Pre-clinical research and development
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands
Investment
Investment opportunity for Pharma and Healthcare Inverstors
- Startup
- Expansion
- Possible Exit
- Innovative therapies
- Growth and Establishment
- Development stages and support fuctions
Rositsa Jordanova
CEO and founder at Protyon
Groningen, Netherlands